OR-USB-IF
27.8.2024 17:01:25 CEST | Business Wire | Press release
USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced the launch of the USB-IF Conformity to IEC 62680 (USB) Specifications Program. This new initiative is designed to assist Original Equipment Manufacturers (OEMs)/Original Device Manufacturers (ODMs) in conforming to the basic requirements of the European Union (EU) Common Charger Directive, which mandates the use of standardized charging technology across a wide range of portable battery-powered devices in the EU.
In response to the EU's 2022 approval of the common charger directive—which will take effect on January 1, 2025, for portable battery-powered devices and in 2026 for laptops—the USB-IF Conformity to IEC 62680 (USB) Specifications Program specifically addresses key aspects of the directive. These include portable battery-powered devices, USB Type-C® receptacles, USB Type-C cables and connectors, external power supplies (EPS), and the USB Power Delivery (USB PD) protocol for devices advertising more than 15 Watts.
“The USB-IF has enjoyed a longstanding relationship with IEC. We contributed the core USB specifications to IEC which, once adopted, became the IEC 62680 series of USB specifications,” said USB-IF President and Chief Operating Officer Jeff Ravencraft. “The EU mandate covers only a portion of the entire USB specifications. As the industry group responsible for developing and overseeing all aspects of the USB specifications and testing, the USB-IF's new program is designed to assist OEMs/ODMs in demonstrating conformity with the EU’s requirements of the common charger directive.”
The USB-IF Conformity to IEC 62680 (USB) Specifications Program creates a simple, cost-effective process for OEMs/ODMs to demonstrate conformity to the EU Common Charger Directive. Using the USB-IF program, OEMs/ODMs can have their USB Type-C products formally tested by USB-IF authorized independent test labs (ITLs). Upon successful completion of testing, OEMs/ODMs will receive documentation to demonstrate to the EU that their products conform to the IEC 62680 (USB) specifications. This streamlined process allows for a quick testing turnaround, ensuring that manufacturers can meet regulatory deadlines:
- OEMs will continue to register their products and submit test results through ITLs, following USB-IF’s already established process.
- A minimum set of required tests has been defined by the USB-IF to demonstrate baseline conformity.
- The USB-IF will review all test result submissions and provide official approval.
- A Vendor ID (VID) is required, and USB-IF will be utilizing a Test ID (TID) as a tracker reference.
"The USB-IF Conformity to IEC 62680 (USB) Specifications Program has been crafted to ensure that all submitted products undergo evaluation, focusing on the critical elements we believe are necessary for conforming with the EU mandate,” said USB-IF Chief Technology Officer and Chairman of the Board Abdul Ismail. “Our testing levels are designed to offer a precise and reliable assessment, enabling OEMs/ODMs to confidently show to the EU that their products conform to the regulatory obligations."
While the USB-IF Conformity to IEC 62680 (USB) Specifications Program provides a vital service to OEMs/ODMs by offering a formal method to demonstrate conformity to EU mandates, it is important to distinguish this from the more extensive USB-IF Compliance Program. The USB-IF Compliance Program offers in-depth testing that not only establishes conformity with the IEC 62680 specifications but also fully verifies a product's adherence to the comprehensive USB-IF specifications for data performance, reliability and interoperability. Additionally, fully certified products qualify to be able to use the Certified USB Logo, which consumers recognize and trust to provide what they have come to expect from USB products.
“While this program is not a full certification of USB technologies, it provides a formalized pathway for OEMs/ODMs to test their products quickly,” said Ravencraft. “We are confident this new program will help the industry achieve conformity so they can continue to sell their products in the EU marketplace."
An online public listing of OEMs/ODMs products that have passed the "USB-IF Conformity to IEC 62680 (USB) Specifications Program" is located on the USB-IF product search page at www.usb.org. This platform also differentiates between products that are fully USB-IF certified and those that have met only the conformity requirements.
About USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827576634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom